Market Overview

Intercept Pharmaceutical Shares Up Amid Deutsche Bank Initiation

Share:
Related ICPT
Intercept Pharma Shares Higher Following New Buy Rating, $465 Target From UBS
Biotech Investors: Nomura Says To Watch These Dates

In a note released Monday morning, Deutsche Bank analyst Alethia Young initiated coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with a Buy rating and a $395 price target.

Young noted that Intercept is in the process of developing its lead asset OCA for the treatment of PBC and NASH.

Looking a head, Young wrote, "We think a stat sig trend on NASH clearance is essential for accelerated FDA approval and to remain competitive."

Young added, " We think shares currently reflect ~35% chance of success for NASH. We see some downside protection in the fact that if NASH fails in Ph2b, the co will likely price PBC higher."

Young is forecasting a price range of $336-$404 per share on good data and $110-$146 per share on bad data.

Shares of Intercept are up 3.4 percent at $229.77.

Latest Ratings for ICPT

DateFirmActionFromTo
Apr 2015UBSInitiates Coverage onBuy
Mar 2015Janney CapitalMaintainsBuyBuy
Mar 2015Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: Alethia Young Deutsche BankAnalyst Color Price Target Initiation Analyst Ratings

 

Related Articles (ICPT)

Around the Web, We're Loving...

Get Benzinga's Newsletters